Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(6):966–971. doi: 10.1038/sj.bjc.6690794

Targeted cytotoxic analogue of bombesin/ gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice

H Kiaris 1,2, A V Schally 1,2, A Nagy 1,2, B Sun 1,2, P Armatis 1,2, K Szepeshazi 1,2
PMCID: PMC2362957  PMID: 10576652

Abstract

Recently, we developed a powerful cytotoxic analogue of bombesin AN-215, in which the bombesin-like carrier peptide Gln–Trp–Ala–Val–Gly–His–Leu–Ψ(CH2-NH)–Leu–NH2 (RC-3094) is conjugated to a potent derivative of doxorubicin, 2-pyrrolinodoxorubicin (AN-201). Small-cell lung carcinomas (SCLCs) are known to express high levels of bombesin receptors. We evaluated whether these receptors could be used for targeting cytotoxic bombesin analogue to H-69 SCLC cells. H-69 cells were xenografted into male nude mice, which then received an intravenous injection of AN-215, cytotoxic radical AN-201, the carrier peptide RC-3094 alone or unconjugated mixture of RC-3094 and AN-201. The levels of mRNA for bombesin receptor subtypes were evaluated by reverse transcription-polymerase chain reaction. In vitro, both the analogue AN-215 and the radical AN-201 showed strong antiproliferative effects on H-69 cells, AN-215 requiring more time to exert its action at 10–8M concentration than AN-201. In vivo, the growth of H-69 SCLC tumours was significantly inhibited by the treatment with 200 nmol kg–1 of AN-215, while equimolar doses of the cytotoxic radical AN-201 or the mixture of AN-201 and the carrier peptide were toxic and produced only a minor tumour inhibition as compared with control groups. mRNA for bombesin receptor subtypes 2 (BRS-2) and 3 (BRS-3) was detected in H-69 tumours. The mRNA levels for BRS-3, but not for BRS-2, were lower in the AN-215-treated tumours as compared with controls. Our results demonstrate that the cytotoxic bombesin analogue AN-215 could be considered for targeted therapy of tumours, such as SCLC, that express bombesin receptors. © 1999 Cancer Research Campaign

Keywords: tumour inhibition, cancer therapy, hormone analogues, tumour targeting, doxorubicin, bombesin receptor, hGRPR, hNMBR, RT-PCR

Full Text

The Full Text of this article is available as a PDF (96.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A., Minna J. D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. 1985 Aug 29-Sep 4Nature. 316(6031):823–826. doi: 10.1038/316823a0. [DOI] [PubMed] [Google Scholar]
  2. Draoui M., Chung P., Park M., Birrer M., Jakowlew S., Moody T. W. Bombesin stimulates c-fos and c-jun mRNAs in small cell lung cancer cells. Peptides. 1995;16(2):289–292. doi: 10.1016/0196-9781(94)00173-1. [DOI] [PubMed] [Google Scholar]
  3. Fathi Z., Corjay M. H., Shapira H., Wada E., Benya R., Jensen R., Viallet J., Sausville E. A., Battey J. F. BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem. 1993 Mar 15;268(8):5979–5984. [PubMed] [Google Scholar]
  4. Koppán M., Halmos G., Arencibia J. M., Lamharzi N., Schally A. V. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer. 1998 Oct 1;83(7):1335–1343. doi: 10.1002/(sici)1097-0142(19981001)83:7<1335::aid-cncr10>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  5. Mantey S. A., Weber H. C., Sainz E., Akeson M., Ryan R. R., Pradhan T. K., Searles R. P., Spindel E. R., Battey J. F., Coy D. H. Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem. 1997 Oct 10;272(41):26062–26071. doi: 10.1074/jbc.272.41.26062. [DOI] [PubMed] [Google Scholar]
  6. Moody T. W., Carney D. N., Cuttitta F., Quattrocchi K., Minna J. D. High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci. 1985 Jul 15;37(2):105–113. doi: 10.1016/0024-3205(85)90413-8. [DOI] [PubMed] [Google Scholar]
  7. Moody T. W., Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci. 1993;52(14):1161–1173. doi: 10.1016/0024-3205(93)90098-n. [DOI] [PubMed] [Google Scholar]
  8. Nagalla S. R., Barry B. J., Creswick K. C., Eden P., Taylor J. T., Spindel E. R. Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6205–6209. doi: 10.1073/pnas.92.13.6205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nagy A., Armatis P., Cai R. Z., Szepeshazi K., Halmos G., Schally A. V. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):652–656. doi: 10.1073/pnas.94.2.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Nagy A., Armatis P., Schally A. V. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2464–2469. doi: 10.1073/pnas.93.6.2464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Orosz A., Schrett J., Nagy J., Bartha L., Schön I., Nyéki O. New short-chain analogs of a substance-P antagonist inhibit proliferation of human small-cell lung-cancer cells in vitro and in vivo. Int J Cancer. 1995 Jan 3;60(1):82–87. doi: 10.1002/ijc.2910600112. [DOI] [PubMed] [Google Scholar]
  12. Pastan I., FitzGerald D. Recombinant toxins for cancer treatment. Science. 1991 Nov 22;254(5035):1173–1177. doi: 10.1126/science.1683495. [DOI] [PubMed] [Google Scholar]
  13. Pinski J., Schally A. V., Halmos G., Szepeshazi K., Groot K., O'Byrne K., Cai R. Z. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer. 1994 Nov;70(5):886–892. doi: 10.1038/bjc.1994.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Plonowski A., Schally A. V., Nagy A., Sun B., Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res. 1999 Apr 15;59(8):1947–1953. [PubMed] [Google Scholar]
  15. Plumb J. A., Milroy R., Kaye S. B. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 1989 Aug 15;49(16):4435–4440. [PubMed] [Google Scholar]
  16. Schally A. V., Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol. 1999 Jul;141(1):1–14. doi: 10.1530/eje.0.1410001. [DOI] [PubMed] [Google Scholar]
  17. Spindel E. R., Giladi E., Segerson T. P., Nagalla S. Bombesin-like peptides: of ligands and receptors. Recent Prog Horm Res. 1993;48:365–391. doi: 10.1016/b978-0-12-571148-7.50017-8. [DOI] [PubMed] [Google Scholar]
  18. Szepeshazi K., Milovanovic S., Lapis K., Groot K., Schally A. V. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat. 1992;21(3):181–192. doi: 10.1007/BF01975001. [DOI] [PubMed] [Google Scholar]
  19. Toi-Scott M., Jones C. L., Kane M. A. Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. Lung Cancer. 1996 Nov;15(3):341–354. doi: 10.1016/0169-5002(95)00597-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES